Idera Pharmaceuticals to Present Positive Phase 1 Trial Results on TLR Antagonist IMO-8400 for the T

Before you go, we thought you'd like these...
Before you go close icon

Idera Pharmaceuticals to Present Positive Phase 1 Trial Results on TLR Antagonist IMO-8400 for the Treatment of Autoimmune Diseases at FOCIS 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc. (NAS: IDRA) today announced that it will present positive Phase 1 trial results on IMO-8400, a selective inhibitor of Toll-like receptors (TLRs) 7, 8 and 9 and a lead candidate for the treatment of autoimmune diseases, at the 13th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS), June 27-30, 2013, in Boston, MA.

Details of the presentation are as follows:

   

Date:

Saturday, June 29, 2013

Time:

6:30-7:45pm ET

Location:

Commonwealth Hall, The Boston Seaport Hotel

Abstract Number:

S.85

Title:

Phase 1 clinical trial of IMO-8400, an antagonist of Toll-like receptors 7, 8 and 9
 

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates and has a clinical development program in autoimmune diseases. Additionally, Idera has a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants for cancer, infectious diseases and Alzheimer's disease. For more information, visit http://www.iderapharma.com.



Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:

The article Idera Pharmaceuticals to Present Positive Phase 1 Trial Results on TLR Antagonist IMO-8400 for the Treatment of Autoimmune Diseases at FOCIS 2013 originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners